Geron surges after winning first US FDA approval for blood disorder drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Geron Corporation (GERN) PT Raised to $6 at Goldman Sachs
June 10, 2024 11:59 AM EDTGoldman Sachs analyst Corinne Jenkins raised the price target on Geron Corporation (NASDAQ: GERN) to $6.00 (from $5.00) while maintaining a Buy rating.
The analyst comments "GERN is trading +19.7% (vs. -1.6% for the XBI) intraday following the FDA approval of Rytelo (imetelstat) in lower-risk myelodysplastic syndrome (LR-MDS).... More
